双歧三联活菌制剂根除幽门螺杆菌的临床研究

目的观察双歧三联活菌制剂根除幽门螺杆菌(Hp)的疗效。方法将107例Hp阳性的慢性胃炎、消化性溃疡患者随机分为2组,对照组53例给予四联疗法(果胶铋、雷贝拉唑、阿莫西林和克拉霉素),试验组54例给予双歧三联活菌制剂和三联疗法(雷贝拉唑、阿莫西林和克拉霉素),疗程均为7 d,观察2组Hp根除率及不良反应发生率。结果对照组和试验组Hp根除率分别为83.0%和83.3%,2组比较差异无统计学意义;对照组和试验组不良反应发生率分别为20.8%和3.7%,2组比较差异有统计学意义。结论三联疗法加用双歧三联活菌制剂能有效提高Hp根除率,并能减少不良反应的发生,可与四联疗法相媲美。

Clinical study on bifid triple viable for eradicating helicobacter pylori

Objective To observe the therapeutic effects of bifid triple viable for eradicating helicobacter pylori(Hp).Methods A total of 170 patients with positive Hp chronic gastritis or peptic ulcer were randomly divided into 2 groups.The control group(n=53) was administered colloidal bismuth pectin,rabeprazole,amoxicillin and clarithromycin while the treatment group(n=54) received bifid triple viable,rabeprazole,amoxicillin and clarithromycin,and both courses of treatment were 7 days.Hp eradication rates and incidences of adverse reactions of both groups were observed.Results Hp eradication rates of the control group and treatment group were 83.0% and 83.3%,respectively.There was no significant difference between the two groups.The incidences of control group and treatment group were respectively 20.8% and 3.7%,which indicated significant statistical difference.Conclusion Triple therapy added bifid triple viable can effectively enhance Hp eradication rate and reduce the occurrence of adverse reactions,which can be comparable to quadruple therapy.